GLP-1 Micronutrient Deficiencies: Vitamins You May Miss
GLP-1 Nutrition
22.4%
Percentage of GLP-1 receptor agonist users diagnosed with a new nutritional deficiency within 12 months, based on a retrospective analysis of 461,382 adults.
Scott Butsch et al., Obesity Pillars, 2025
Scott Butsch et al., Obesity Pillars, 2025
View as imageA retrospective study of 461,382 adults newly prescribed GLP-1 receptor agonists found that 12.7% received a new nutritional deficiency diagnosis within six months, rising to 22.4% at one year.[1] That number is striking for a class of drugs prescribed primarily for metabolic improvement. Semaglutide, tirzepatide, and liraglutide suppress appetite and slow gastric emptying, mechanisms that drive weight loss but also reduce the total volume of food, and therefore micronutrients, entering the body. The result is a growing evidence base documenting specific vitamin and mineral deficits that emerge during therapy, a pattern of GLP-1 micronutrient deficiencies distinct from what occurs during general caloric restriction alone.
This article maps the current evidence across each at-risk nutrient, explains the mechanisms behind each deficit, and connects to deeper coverage of caloric intake on GLP-1 therapy, meal planning on tirzepatide, what to eat on semaglutide, and how GLP-1 drugs change your relationship with food.
Key Takeaways
- 22.4% of 461,382 GLP-1 RA users received a new nutritional deficiency diagnosis within 12 months (Scott Butsch et al., 2025)
- Vitamin D deficiency was the most prevalent, reaching 13.6% incidence at one year, with GLP-1 users averaging only 20% of recommended vitamin D intake (Johnson et al., 2025)
- GLP-1 RA users showed 26-30% lower ferritin levels compared to SGLT2 inhibitor users in the same retrospective cohort (Scott Butsch et al., 2025)
- A pharmacovigilance review identified 15 cases of Wernicke encephalopathy linked to GLP-1 RAs, most involving semaglutide or tirzepatide (Lev et al., 2026)
- More than 60% of GLP-1 users consumed below estimated requirements for calcium and iron in a 3-day dietary record analysis (Johnson et al., 2025)
- A joint advisory from four major medical societies now recommends protein intake of 1.2-2.0 g/kg/day and routine micronutrient monitoring during GLP-1 therapy (Mozaffarian et al., 2025)
How GLP-1 Drugs Create Nutrient Gaps
GLP-1 receptor agonists reduce food intake through three interconnected mechanisms: central appetite suppression via hypothalamic signaling, delayed gastric emptying that prolongs satiety, and altered gut motility that changes how nutrients interact with absorptive surfaces.[2] These mechanisms are effective for weight reduction, but they create a nutritional trade-off that has only recently received systematic study. A cross-sectional study of 69 adults using GLP-1 RAs documented the downstream effects: participants consistently fell short of Dietary Reference Intakes for calcium, iron, magnesium, potassium, and vitamins A, C, D, E, and K.[3]
The caloric math is straightforward but often overlooked. Observed caloric reductions during GLP-1 therapy range from 16% to 39%.[4] At intakes below 1,200 kcal/day for women or 1,800 kcal/day for men, meeting micronutrient requirements through food alone becomes mathematically difficult regardless of diet quality. Even a nutritionally optimal 1,200-calorie diet would struggle to provide adequate amounts of all essential vitamins and minerals. Gastrointestinal side effects (nausea, vomiting, diarrhea) compound this problem by reducing the fraction of consumed nutrients that actually gets absorbed. For a deeper exploration of how caloric thresholds interact with nutritional adequacy, see caloric intake on GLP-1 therapy.
A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) cataloged metabolic and nutritional adverse events across different GLP-1 RAs, confirming that decreased appetite, weight decrease, and metabolic disturbances represent the most frequently reported signals for this drug class.[5] The analysis spanned multiple agents and found that while adverse event profiles varied somewhat between individual drugs, the nutritional signal was consistent across the class.
The pattern extends beyond simple undereating. A secondary analysis of liraglutide trial data found that the drug shifted macronutrient distribution, with participants consuming proportionally less protein and more carbohydrate over the treatment period.[6] This shift compounds micronutrient risk because protein-rich foods tend to be the densest sources of iron, zinc, and B vitamins. The alteration in food preferences, explored in depth in our article on how GLP-1 drugs change your relationship with food, means that even when patients eat the same number of calories, the micronutrient density of those calories may decline.
Vitamin D: The Most Common Deficiency
Vitamin D deficiency appeared more frequently than any other nutrient gap in GLP-1 users. In the 461,382-person retrospective cohort, new vitamin D deficiency diagnoses reached 7.5% at six months and 13.6% at twelve months.[1] A narrative review synthesizing six studies encompassing over 480,000 adults confirmed vitamin D as the single most common deficiency associated with GLP-1 RA therapy.[7]
Three mechanisms converge to explain this finding. First, vitamin D is fat-soluble and sequestered in adipose tissue. During rapid weight loss, serum levels may transiently rise as fat stores release vitamin D, but this masks depleting total body stores. Second, dietary vitamin D intake among GLP-1 users averaged only 20% of recommendations in a 3-day food record analysis.[3] Third, many GLP-1 users had pre-existing vitamin D insufficiency before starting therapy. Obesity itself is associated with lower serum 25(OH)D levels due to volumetric dilution in larger body compartments, so the population entering GLP-1 treatment already carries elevated baseline risk.
A real-world analysis of GLP-1 RA impact on calcium homeostasis found perturbations in calcium-vitamin D axis markers among treated patients, suggesting the deficiency has functional downstream consequences beyond low serum levels.[8] These functional changes have implications for bone health, immune function, and muscle performance, all systems that depend on adequate vitamin D signaling.
The clinical trajectory matters as well. Deficiency rates nearly doubled between the 6-month and 12-month marks in the retrospective cohort, indicating that vitamin D status does not stabilize during treatment but continues to deteriorate. This progressive decline argues against the assumption that an initial assessment is sufficient and supports periodic reassessment during ongoing therapy.
Iron: A Quiet Decline
Iron depletion during GLP-1 therapy operates through both reduced intake and impaired absorption. In the large retrospective cohort, GLP-1 RA users demonstrated 26-30% lower ferritin levels compared to SGLT2 inhibitor users, a comparator group with similar metabolic profiles but different drug mechanisms.[1] More than 60% of GLP-1 users consumed below estimated average requirements for iron in the cross-sectional dietary analysis.[3]
The absorption side of the equation adds a layer that dietary adjustment alone may not solve. A murine model of liraglutide demonstrated direct effects on iron homeostasis pathways, suggesting GLP-1 receptor activation may alter iron metabolism independent of reduced food intake.[9] While this finding comes from animal research and may not translate directly to humans, it points to a pharmacological mechanism beyond caloric restriction. Delayed gastric emptying may also reduce iron bioavailability by altering the pH environment in which non-heme iron is most efficiently absorbed. Gastric acid plays a critical role in reducing ferric iron (Fe3+) to the more absorbable ferrous form (Fe2+), and prolonged gastric transit disrupts this process.
The clinical significance is compounded by the macronutrient shift toward lower protein intake observed during GLP-1 therapy.[6] Heme iron from meat is two to three times more bioavailable than plant-based non-heme iron, so dietary patterns that reduce animal protein disproportionately reduce the most absorbable form of iron. Premenopausal women on GLP-1 therapy face compounded risk due to menstrual iron losses, though no study has yet stratified iron outcomes by sex and menstrual status in this population.
Thiamine (Vitamin B1): The Neurological Risk
Thiamine deficiency represents the most clinically alarming nutrient gap in GLP-1 users, not because of its prevalence but because of its consequences. A pharmacovigilance study combined FAERS data with a literature review and identified 15 cases of Wernicke encephalopathy associated with GLP-1 RA use. Most cases involved semaglutide (8 of 15) or tirzepatide (6 of 15) and were reported in 2023-2024.[10]
The case reports follow a consistent pattern. A 37-year-old male on semaglutide presented with dysphagia, slurred speech, restricted eye movements, and over 70 pounds of weight loss. Brain imaging revealed characteristic lesions in the mammillary bodies and periaqueductal gray, confirming Wernicke encephalopathy from thiamine depletion.[11] A separate case documented a 37-year-old woman on semaglutide who developed progressive leg numbness and vision changes within three months, diagnosed as non-alcoholic Wernicke encephalopathy combined with treatment-induced neuropathy.[12]
Thiamine stores in the body are limited, typically lasting only 2-3 weeks without replenishment. Persistent nausea and vomiting, common GLP-1 side effects, accelerate depletion. The combination of reduced intake, GI losses, and low body stores creates a timeline in which severe deficiency can develop within weeks rather than months. Wernicke encephalopathy is a medical emergency: untreated, it progresses to Korsakoff syndrome (permanent anterograde amnesia) in approximately 80% of cases. The fact that it has now been documented in GLP-1 users without any history of alcohol abuse broadens the at-risk population for this diagnosis.
A case of severe lumbosacral polyradiculopathy in a patient on semaglutide following bariatric surgery demonstrated that combined interventions compound the risk dramatically.[13] The patient developed multiple concurrent micronutrient deficiencies, illustrating how GLP-1 therapy layered on top of post-surgical malabsorption can accelerate nutritional decline.
Vitamin B12 and Other B Vitamins
B12 deficiency during GLP-1 therapy intersects with a pre-existing risk factor: metformin use. Many patients prescribed GLP-1 RAs for type 2 diabetes are already taking metformin, which independently reduces B12 absorption through alterations in ileal calcium-dependent B12 uptake. A meta-analysis of metformin studies found that long-term use increased the odds of B12 deficiency by 13% per year of treatment. The combination of metformin and a GLP-1 RA creates additive risk from two distinct mechanisms: reduced ileal absorption from metformin and reduced dietary intake from GLP-1-mediated appetite suppression.
In the narrative review by Urbina et al. (2026), B12 and zinc concentrations declined over 12 months of semaglutide treatment.[7] The decline accompanied a macronutrient shift from protein to carbohydrate, consistent with reduced consumption of B12-rich animal products. B12 deficiency progresses slowly because the liver stores several years' worth of the vitamin, but subclinical depletion during GLP-1 therapy may set a trajectory toward clinical deficiency that manifests months or years after treatment ends.
Folate deficiency has received less attention in the GLP-1 literature specifically, but the mechanisms of reduced intake and GI disruption apply equally to this water-soluble vitamin. For patients taking metformin alongside a GLP-1 RA, the overlapping mechanisms for B12 depletion warrant periodic monitoring, particularly in those who have been on metformin for more than three years.
Calcium and Bone Health
Calcium intake fell below estimated requirements in over 60% of GLP-1 users studied.[3] Combined with widespread vitamin D deficiency, this creates conditions for accelerated bone mineral density loss during the rapid weight reduction phase. Weight loss itself reduces mechanical loading on bone, a stimulus for maintaining density, so the nutritional deficit compounds a biomechanical one.
A real-world study of GLP-1 RA effects on calcium homeostasis found measurable perturbations in calcium balance markers among treated patients, with changes in serum calcium and parathyroid hormone levels that suggest active compensatory bone resorption.[8] The concern is particularly relevant during rapid weight loss phases, when bone remodeling accelerates. Bone turnover markers increase during active weight loss, and without adequate calcium and vitamin D to support new bone formation, the net result is bone loss.
A review comparing GLP-1 therapy to metabolic bariatric surgery noted that both interventions produce similar patterns of nutritional risk, but bariatric surgery patients benefit from established post-operative supplementation protocols that do not yet have equivalents in GLP-1 prescribing.[14] Bariatric patients typically receive 1,200-1,500 mg of calcium citrate daily alongside 3,000 IU of vitamin D3, a protocol developed over decades of post-surgical monitoring. No equivalent standardized protocol exists for GLP-1 patients despite similar weight loss magnitudes.
The joint advisory from four major medical societies specifically flagged calcium alongside protein as nutrients requiring active management during GLP-1 therapy, noting that the combination of inadequate calcium, low vitamin D, reduced mechanical loading, and potential loss of lean mass creates a convergent risk for bone health.[4]
Protein and Lean Mass: The Macronutrient Gap
Protein deficiency during GLP-1 therapy is technically a macronutrient issue, but its consequences intersect directly with micronutrient status. A systematic review of body composition changes during GLP-1 RA therapy found that lean soft tissue loss comprised 26-40% of total weight lost in clinical trials.[15] Inadequate protein intake accelerates this lean mass loss and simultaneously reduces intake of the micronutrients most concentrated in protein-rich foods: iron, zinc, B12, and B6.
The joint advisory recommended protein intake of 1.2-2.0 g/kg/day during GLP-1 therapy, substantially above typical intakes observed in clinical studies.[4] For a 180-pound (82 kg) person, that translates to 98-164 grams of protein daily. Meeting this target at reduced caloric intakes requires deliberate dietary planning, because protein at these levels would need to comprise 30-50% of total calories on a 1,200-1,500 calorie intake. A secondary analysis of a liraglutide trial found that protein as a proportion of total calories actually decreased during treatment, driven by the combination of reduced appetite for protein-rich foods and relative preservation of carbohydrate intake.[6]
This has direct implications for nutrition planning on tirzepatide and for the related concern of GLP-1 weight loss and sarcopenia in older adults. Older adults on GLP-1 therapy face the highest risk from the protein-lean mass nexus, as age-related anabolic resistance means they require more protein per kilogram to maintain the same muscle mass compared to younger adults.
Zinc, Magnesium, and Trace Minerals
Zinc and magnesium emerge as consistent gaps in the GLP-1 dietary intake data. The cross-sectional study of 69 GLP-1 users found inadequate intakes of both minerals relative to dietary reference values.[3] Over 12 months of semaglutide treatment, zinc concentrations declined alongside B12.[7] Zinc plays essential roles in immune function, wound healing, and taste perception. Loss of taste (dysgeusia) during GLP-1 therapy, often attributed to the drug itself, may in some cases reflect zinc depletion, though this connection has not been studied directly in GLP-1 populations.
Magnesium deficiency carries particular significance for GLP-1 users with type 2 diabetes. Magnesium is a cofactor in insulin signaling pathways, and low magnesium levels are independently associated with worsened insulin resistance. For patients using GLP-1 RAs to improve glycemic control, magnesium depletion could partially undermine the metabolic benefits of treatment.
A case of carnitine deficiency in a patient on oral semaglutide raised the broader question of whether the drug's excipient (salcaprozate sodium, used to enhance oral absorption) may independently affect nutrient transport systems.[16] This represents a mechanism distinct from reduced intake and suggests that oral formulations may carry different micronutrient risk profiles than injectable versions. The finding is preliminary and from a single case in a patient with an underlying metabolic disorder, but it opens a line of inquiry about formulation-specific effects.
Selenium intake appeared adequate in the cross-sectional dietary analysis,[3] but the data on trace mineral status during GLP-1 therapy remains thin. Most studies measure deficiency diagnoses or dietary intake rather than serial serum levels, leaving gaps in understanding how subclinical depletion develops over time.
What the Bariatric Literature Can Teach GLP-1 Prescribers
The parallel between GLP-1 therapy and bariatric surgery is instructive. Both produce substantial weight loss (15-25% of body weight), alter GI physiology, and create measurable nutritional risk. The difference is that bariatric surgery has decades of post-operative nutritional protocols, while GLP-1 prescribing has historically treated nutrition as an afterthought.[14] Bariatric programs routinely screen for vitamin D, B12, iron, folate, calcium, thiamine, and copper at baseline and at regular intervals post-operatively. They prescribe specific supplementation regimens from day one, not reactively after deficiency develops.
The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society represents the first formal attempt to close this gap for GLP-1 prescribing.[4] Key recommendations include routine monitoring of vitamin D, B12, iron studies, and metabolic panels; protein targets of 1.2-2.0 g/kg/day; and consideration of multivitamin supplementation for patients on extended GLP-1 therapy. The advisory also emphasized dietitian involvement as part of the treatment team, a practice standard in bariatric care that remains uncommon in GLP-1 prescribing.
A narrative review of dietary supplement considerations during GLP-1 RA treatment noted that while supplementation guidelines are still emerging, the evidence supports proactive rather than reactive approaches, particularly for patients with pre-existing nutritional risk factors or those experiencing significant GI side effects.[17] The review highlighted that timing of supplementation matters: taking supplements during periods of active nausea may reduce absorption, while spacing supplements away from GLP-1 injections could improve tolerance.
The question is not whether GLP-1 users develop nutritional deficiencies. The data confirms they do. The question is which nutrients to monitor, how frequently, and at what threshold to intervene. These questions are the subject of ongoing research, and definitive answers do not yet exist for most specific nutrients. For practical strategies on maintaining nutritional adequacy during treatment, see our articles on what to eat on semaglutide and meal planning on tirzepatide.
Limitations of the Current Evidence
The evidence base has real constraints that affect the confidence with which any specific recommendation can be made. The largest study (461,382 patients) relied on claims data, which captures diagnosed deficiencies but misses subclinical depletion.[1] Diagnosis rates depend on whether clinicians order labs, creating detection bias. Clinicians who are aware of the nutritional risk may test more often and therefore diagnose more deficiencies, while those who are unaware may miss the same deficiencies. The true prevalence of suboptimal nutrient status likely exceeds the 22.4% diagnosed rate.
The cross-sectional dietary study included only 69 participants and measured intake rather than serum levels.[3] Dietary intake records are inherently imprecise and subject to underreporting. Most body composition data comes from clinical trials with controlled conditions that may not reflect real-world eating patterns, where adherence to dietary guidance is typically lower.
No randomized controlled trial has yet been designed with micronutrient status as a primary endpoint during GLP-1 therapy. The case reports of Wernicke encephalopathy, while alarming, represent rare events in a treated population now numbering tens of millions. The pharmacovigilance data from FAERS carries inherent reporting bias, as adverse events are more likely to be reported when they are severe or when the association with a drug is novel.
What the evidence does establish clearly: reduced caloric intake during GLP-1 therapy creates measurable nutritional risk across multiple nutrient categories; specific nutrients (vitamin D, iron, thiamine, B12, calcium) emerge consistently across different study designs and populations; and the risk increases with treatment duration. The convergence of findings from large retrospective studies, dietary intake analyses, pharmacovigilance databases, and case reports builds a case for proactive monitoring, even if the precise screening intervals remain undefined.
The Bottom Line
GLP-1 receptor agonists produce weight loss partly by reducing food intake, which simultaneously reduces micronutrient consumption. A 461,382-person retrospective study found 22.4% of users received a nutritional deficiency diagnosis within one year. Vitamin D, iron, B vitamins (especially thiamine and B12), calcium, zinc, and protein consistently emerge as the highest-risk nutrients across multiple study types. A 2025 joint advisory from four major medical societies recommended proactive monitoring and protein targets of 1.2-2.0 g/kg/day, though no randomized trial has yet defined optimal screening protocols for this specific population.